2025-08-08 - Analysis Report
Okay, here's the report summarizing the information provided on Recursion Pharmaceuticals Inc. (RXRX).

## RXRX (Recursion Pharmaceuticals Inc.) Stock Analysis

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

**Key Numbers:**

*   **RXRX Cumulative Return:** -45.78%
*   **VOO Cumulative Return:** 38.35%
*   **Absolute Divergence:** -78.3%
*   **Relative Divergence:** 7.9%

**Analysis:**

RXRX has significantly underperformed the S&P 500 (VOO) over the tracked period.  The -78.3% absolute divergence highlights the stark contrast in returns.  The relative divergence of 7.9% indicates that RXRX's underperformance is near its worst relative level compared to the VOO within the tracked historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2021-2023  | 5.0%  | 73.6% | -4.0%  | 0.0 | 4.3   |
| 2022-2024  | 0.0%  | 73.6% | -26.0% | 0.0 | 2.9   |
| 2023-2025  | 6.0%  | 73.6% | -42.0% | 0.0 | 2.4   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows inconsistent performance.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high at 73.6%, indicating significant risk and volatility.
*   **Alpha:** Negative Alpha values indicate underperformance relative to the benchmark on a risk-adjusted basis. The trend suggests worsening alpha over time.
*   **Beta:** A Beta of 0.0 indicates that the stock's price is not correlated with the market (S&P 500).
*   **Cap:** Market capitalization has decreased from 4.3 billion to 2.4 billion from 2021 to 2025.

### 2. Recent Stock Price Movement

**Key Numbers:**

*   **Current Price:** \$5.41
*   **Previous Close:** \$5.48
*   **Change:** -1.28%
*   **5-day Moving Average:** \$5.58
*   **20-day Moving Average:** \$5.83
*   **60-day Moving Average:** \$5.19

**Analysis:**

The stock price has slightly decreased by 1.28%. The 5-day and 20-day moving averages are above the current price, suggesting a recent downward trend.  The 60-day moving average is below the current price, indicating a longer-term upward trend, though recent price action suggests this may be weakening.

### 3. Market Risk Indicators and Expected Return

**Key Numbers:**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 42.35
*   **PPO:** -1.98
*   **Hybrid Signal:** cash_70%_Sell 70.0% of holdings
*   **Recent (20-day) Relative Divergence Change:** 0.3 (+, Short-term Increase)
*   **Expected Return:** -299.1%

**Analysis:**

*   **MRI:** The MRI indicates a "Low Risk" environment.
*   **RSI:**  An RSI of 42.35 suggests the stock is neither overbought nor oversold, indicating neutral momentum.
*   **PPO:**  A negative PPO (-1.98) suggests that the short-term moving average is below the long-term moving average, indicating a potential downtrend.
*   **Hybrid Signal:** The signal recommends selling 70% of holdings and increasing the cash ratio to 70%. This is a strong bearish signal.
*   **Relative Divergence Change:** The recent increase in relative divergence suggests a short-term upward trend, potentially a minor recovery.
*   **Expected Return:**  The extremely negative expected return (-299.1%) indicates a very pessimistic outlook for long-term investment compared to the S&P 500.

The recent price change of -1.28% reflects a small downward fluctuation.

### 4. Recent News & Significant Events

*   **2025-08-08:** Major business developments, regulatory changes, or market events.
*   **2025-08-05:** Analyst discussions on recent performance and outlook.
*   **2025-08-06:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-08-07:** Market experts highlight both risks and opportunities.

**Analysis:**

Recent news suggests volatility and potential uncertainty surrounding RXRX. Investors should closely monitor company announcements and market developments.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출     |
|------------|--------|----------|
| 2025-08-05 | -0.41  | 0.02 B$  |
| 2025-05-05 | -0.5   | 0.01 B$  |
| 2024-11-06 | -0.34  | 0.03 B$  |
| 2024-08-08 | -0.4   | 0.01 B$  |
| 2025-08-05 | -0.4   | 0.01 B$  |

**Analysis:**

*   The company has consistently reported negative EPS (Earnings Per Share), indicating a lack of profitability.
*   Revenue figures are relatively low and fluctuate. This raises concerns about the company's revenue generation capabilities.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | \$0.02B | -5.54%        |
| 2025-03-31   | \$0.01B | -47.31%       |
| 2024-12-31   | \$0.00B | -183.62%      |
| 2024-09-30   | \$0.03B | 53.69%        |
| 2024-06-30   | \$0.01B | 36.14%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-06-30   | \$0.92B   | -18.70%   |
| 2025-03-31   | \$0.93B   | -21.68%   |
| 2024-12-31   | \$1.03B   | -17.29%   |
| 2024-09-30   | \$0.52B   | -18.27%   |
| 2024-06-30   | \$0.58B   | -16.69%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue is inconsistent, and profit margins are generally negative, except for two quarters in 2024. The highly negative profit margin in 2024-12-31 is particularly concerning.
*   **Capital and Profitability:** Equity has fluctuated significantly, and ROE (Return on Equity) is consistently negative, indicating poor profitability relative to shareholder equity.

### 7. Overall Summary

RXRX has significantly underperformed the S&P 500, exhibiting high volatility and a negative alpha. Recent price action indicates a downtrend, and the hybrid signal suggests a strong sell recommendation. The company's earnings and financial information reveal consistent losses and fluctuating revenue. While the MRI indicates a low-risk market environment, the expected return is extremely negative, suggesting a pessimistic outlook for long-term investment. Recent news indicates volatility and uncertainty.

**Recommendation:**

Based on this analysis, a cautious approach is warranted. Given the negative expected return, consistent losses, and significant underperformance compared to the S&P 500, investors should exercise caution and closely monitor company developments before considering investment. The hybrid signal suggests reducing exposure to the stock.
